Is the 'loss of resistance' technique with hydrodissection during fascial plane blocks feasible?

Eur J Anaesthesiol

From the Department of Anaesthetics, Kent and Canterbury Hospital, Canterbury, UK (BMM).

Published: October 2024

Download full-text PDF

Source
http://dx.doi.org/10.1097/EJA.0000000000002037DOI Listing

Publication Analysis

Top Keywords

'loss resistance'
4
resistance' technique
4
technique hydrodissection
4
hydrodissection fascial
4
fascial plane
4
plane blocks
4
blocks feasible?
4
'loss
1
technique
1
hydrodissection
1

Similar Publications

Introduction: The WHO endorsed the Xpert MTB/RIF (Xpert) technique since 2011 as initial test to diagnose rifampicin-resistant tuberculosis (RR-TB). No systematic review has quantified the proportion of pretreatment attrition in RR-TB patients diagnosed with Xpert in high TB burden countries.Pretreatment attrition for RR-TB represents the gap between patients diagnosed and those who effectively started anti-TB treatment regardless of the reasons (which include pretreatment mortality (death of a diagnosed RR-TB patient before starting adequate treatment) and/or pretreatment loss to follow-up (PTLFU) (drop-out of a diagnosed RR-TB patient before initiation of anti-TB treatment).

View Article and Find Full Text PDF

Nano zero-valent iron (nZVI) is widely used for polychlorinated biphenyl (PBDE) remediation due to its cost-effectiveness and strong reduction capacity. However, its practical application is limited by poor stability, mobility, and antioxidant performance, as well as high reactivity that leads to side reactions and activity loss. To overcome these challenges, a poly(styrene)-encapsulated nZVI (PS-nZVI) core-shell structure was developed using dispersion polymerization.

View Article and Find Full Text PDF

Millets are drought-resistant crops that generate significant amount of by-products (bran, husk, stalk etc.) during harvesting and processing. These by-products are storehouse of nutrients and high value compounds including polyphenols, dietary fiber, proteins etc.

View Article and Find Full Text PDF

Rebound bone loss following denosumab discontinuation is an important barrier in the effective long-term treatment of skeletal disorders. This is driven by increased osteoclastic bone resorption following the offset of RANKL inhibition, and sequential osteoclast-directed therapy has been utilised to mitigate this. However, current sequential treatment strategies intervene following the offset of RANKL inhibition and this approach fails to consistently prevent bone loss.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!